|
|
Lymphoma Studies Currently Recruiting Participants at the Simmons Cancer Research Center at Southern Illinois University School of Medicine
| Protocol Title |
Study # |
Study Group |
| Central Nervous System Lymphoma |
| A Phase I/II Study of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, and Temozolomide and Post -Irradiation Temozolomide for Primary Central Nervous System Lymphoma |
RTOG 0227 |
RTOG |
| Hodgkin's Lymphoma |
| A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging |
SWOG S0816 |
CICCOP |
| Non-Hodgkin’s Lymphoma |
| Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma |
COG AALL0434 |
SCI COG |
| Phase II Randomized Trial of the Combination of ABT-888 With Metronomic Oral Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low‑Grade Non-Hodgkin’s Lymphoma. |
SCI 11-022 |
SCI |
| A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma |
ECOG 2408 |
CICCOP |
| A Prospective, Longitudinal. Multinational Registry for Patients with Newly diagnosed T-Cell lymphoma. |
10-017 |
SCI |
| Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas. |
10-061 |
SCI |
| Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas |
CTSU/ CALGB 50303 |
CICCOP |
Although our objective is to provide an updated listing of available clinical trials please note that a listing here does not guarantee that a trial is open or available to any specific patient and that there may be additional trials available that are not listed. Complete information is only available from a treating physician.
Contact Information:
Simmons Cancer Institute Clinical Trials Office
Mail Code 9677 Fax (217) 545-6823
- Kathy Robinson, PhD,
Director of Clinical Trials
(217) 545-1946
-
Allicent Curry, RN,BSN, OCN
Research Nurse
(217) 545-7929 -
-
-
-
-
SIU Behavioral & Psychosocial Oncology
- Anna Wiggins, MS, LCPC
(217) 545-5408
-
SIU COG
- Carol Peterson, RN, CCRP (217) 545-7377
SIU IM
- Amanda Fogleman, B.S. (217) 545-0592
- Krista Whitlock (217) 545-7750
SIU Thoracic
- Theresa Boley, RN, MSN, APN/FNP-BC, CCRP (217) 545-5000
-
- Cathy Leslie, RN, CCRP (217) 545-8184
- Mary Ray, MS (217) 545-7420
-
RTOG: Radiation Therapy Oncology Group:
- Diana Weyhenmeyer, RN, MA, OCN (217) 544-6464 ext. 45591
CICCOP: Central Illinois Community Clinical Oncology Program
Memorial Medical Center CICCOP Research Contacts:
Treatment/Cancer Control:
- Holly Thomas (217) 788-4178
- Stephanie Allbritton (217) 788-3544
- Brooke Trickey (217) 217-788-3560
- Karen Graber (217) 588-2961
- Chrissy Tucker (217) 788-4444
Sunny Hampsey (217) 788-4233
Back to Open Clinical Trials
|
 |
|
